Company / Cash & Equivalents
Glucose Health, Inc. Cash & Equivalents History
FY2011-FY2016 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$20.5K
FY2016
5-year range
$711 / $20.5K
FY2012-FY2016
Trend
+899.6%
vs FY2015
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cash & Equivalents changed +900% YoY in FY2016, a notable deviation from the 4-year average annual change of +336%.
Based on SEC 10-K filings.
$20,542 in FY2016 with a 5-year CAGR of +39.2%.
Improved from $4,871 to $20,542 over the past 2 years.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +206.8%
- 5-Year CAGR
- +39.2%
- 10-Year CAGR
- -
Key checks
Key Insights
- 5-year CAGR of +39.2%, indicating consistent growth.
- In FY2016, cash & equivalents increased 899.6% year-over-year.
- Lowest cash & equivalents in the period was in FY2013.
Company context
Key Data Points
- Altman Z-Score -169.46 (distress zone, below 1.23 threshold)
- Cash-backed earnings: Operating cash flow exceeds net income
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2016 | $20.5K | +899.6% |
| FY2015 | $2.1K | -57.8% |
| FY2014 | $4.9K | +585.1% |
| FY2013 | $711 | -81.9% |
| FY2011 | $3.9K | - |